| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gerhard Gründer, Christian Landvogt, Ingo Vernaleken, Hans-Georg Buchholz, Jasmin Ondracek, Thomas Siessmeier, Sebastian Härtter, Mathias Schreckenberger, Peter Stoeter, Christoph Hiemke, Frank Rösch, Dean F Wong, Peter Bartenstei. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 5. 2006-06-06. PMID:16237387. |
the striatal and extrastriatal d2/d3 receptor-binding profile of clozapine in patients with schizophrenia. |
2006-06-06 |
2023-08-12 |
human |
| Gerhard Gründer, Christian Landvogt, Ingo Vernaleken, Hans-Georg Buchholz, Jasmin Ondracek, Thomas Siessmeier, Sebastian Härtter, Mathias Schreckenberger, Peter Stoeter, Christoph Hiemke, Frank Rösch, Dean F Wong, Peter Bartenstei. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 5. 2006-06-06. PMID:16237387. |
here, the occupancy of d2/d3 dopamine receptors by clozapine in patients with schizophrenia was determined to test the hypothesis that clozapine binds preferentially to extrastriatal dopamine receptors. |
2006-06-06 |
2023-08-12 |
human |
| Yi-Yung Hung, Ping-Suen Yang, Tiao-Lai Huan. Clozapine in schizophrenia patients with recurrent catatonia: report of two cases. Psychiatry and clinical neurosciences. vol 60. issue 2. 2006-06-06. PMID:16594953. |
clozapine in schizophrenia patients with recurrent catatonia: report of two cases. |
2006-06-06 |
2023-08-12 |
Not clear |
| Stefan Bender, Alexandra Dittmann-Balcar, Ulrich Schall, Jörg Wolstein, Ansgar Klimke, Michael Riedel, Ernst-Ulrich Vorbach, Kai-Uwe Kühn, Martin Lambert, Ralf W Dittmann, Dieter Nabe. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. The international journal of neuropsychopharmacology. vol 9. issue 2. 2006-05-25. PMID:16174427. |
influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. |
2006-05-25 |
2023-08-12 |
Not clear |
| Ellas K Nanitsos, Khoa T D Nguyen, Frantisek St'astný, Vladimir J Balca. Glutamatergic hypothesis of schizophrenia: involvement of Na+/K+-dependent glutamate transport. Journal of biomedical science. vol 12. issue 6. 2006-05-25. PMID:16228297. |
the model is consistent with actions of neuroleptics, such as clozapine, in animal experiments and it is strongly supported by recent findings of increased expression of glutamate transporter glt in prefrontal cortex of patients with schizophrenia. |
2006-05-25 |
2023-08-12 |
Not clear |
| Joseph P McEvoy, Jeffrey A Lieberman, T Scott Stroup, Sonia M Davis, Herbert Y Meltzer, Robert A Rosenheck, Marvin S Swartz, Diana O Perkins, Richard S E Keefe, Clarence E Davis, Joanne Severe, John K Hsia. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American journal of psychiatry. vol 163. issue 4. 2006-05-24. PMID:16585434. |
effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. |
2006-05-24 |
2023-08-12 |
Not clear |
| Joseph P McEvoy, Jeffrey A Lieberman, T Scott Stroup, Sonia M Davis, Herbert Y Meltzer, Robert A Rosenheck, Marvin S Swartz, Diana O Perkins, Richard S E Keefe, Clarence E Davis, Joanne Severe, John K Hsia. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American journal of psychiatry. vol 163. issue 4. 2006-05-24. PMID:16585434. |
when a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. |
2006-05-24 |
2023-08-12 |
Not clear |
| Fayçal Mouaffak, Constantin Tranulis, Raphaël Gourevitch, Marie-France Poirier, Saida Douki, Jean-Pierre Olié, Henri Lôo, David Gourio. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clinical neuropharmacology. vol 29. issue 1. 2006-05-09. PMID:16518132. |
augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. |
2006-05-09 |
2023-08-12 |
Not clear |
| Beata J Havaki-Kontaxaki, Panayotis P Ferentinos, Vassilis P Kontaxakis, Konstantinos G Paplos, Constantin R Soldato. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clinical neuropharmacology. vol 29. issue 1. 2006-05-09. PMID:16518135. |
concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. |
2006-05-09 |
2023-08-12 |
Not clear |
| Guido Grass, Martin Hellmich, F Markus Lewek. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. The New England journal of medicine. vol 354. issue 17. 2006-05-03. PMID:16641404. |
clozapine alone versus clozapine and risperidone for refractory schizophrenia. |
2006-05-03 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, A Elif Anil Yağcioğlu, Berna Binnur Kivircik Akded. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. The New England journal of medicine. vol 354. issue 17. 2006-05-03. PMID:16642583. |
clozapine alone versus clozapine and risperidone for refractory schizophrenia. |
2006-05-03 |
2023-08-12 |
Not clear |
| Stanton L Gerso. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. The New England journal of medicine. vol 354. issue 17. 2006-05-03. PMID:16642587. |
clozapine alone versus clozapine and risperidone for refractory schizophrenia. |
2006-05-03 |
2023-08-12 |
Not clear |
| Yiu-Chung Chan, Mary Beth Hankin. Clozapine as a short-term antipsychotic medication in patients with schizophrenia. Schizophrenia research. vol 81. issue 1. 2006-05-02. PMID:16243491. |
clozapine as a short-term antipsychotic medication in patients with schizophrenia. |
2006-05-02 |
2023-08-12 |
Not clear |
| S Sondhi, J M Castellano, V Z Chong, R M Rogoza, K J Skoblenick, B A Dyck, J Gabriele, N Thomas, K Ki, Z B Pristupa, A N Singh, D MacCrimmon, P Voruganti, J Foster, R K Mishr. cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects. The pharmacogenomics journal. vol 6. issue 2. 2006-04-28. PMID:16402076. |
unlike the typical antipsychotic drug, haloperidol, clozapine does not cause extrapyramidal side effects; however, weight gain, dyslipidemia, and type ii diabetes are commonly associated with the use of this drug in subjects with schizophrenia. |
2006-04-28 |
2023-08-12 |
human |
| J P Lindenmayer, Anzalee Kha. Pharmacological treatment strategies for schizophrenia. Expert review of neurotherapeutics. vol 4. issue 4. 2006-04-20. PMID:15853589. |
the pharmacological choices for the treatment of schizophrenia have been greatly expanded with the availability of the atypical compounds clozapine (clozaril, novartis), risperidone (risperdal, janssen-cilag), olanzapine (zyprexa, eli lilly & co.), quetiapine (seroquel, astrazeneca), ziprasidone (geodon, pfizer inc.) and aripiprazole (abilify, otsuka pharmaceutical co. ltd). |
2006-04-20 |
2023-08-12 |
Not clear |
| Bruce L Lambert, Chia-Hung Chou, Ken-Yu Chang, Eskinder Tafesse, William Carso. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiology and drug safety. vol 14. issue 6. 2006-04-19. PMID:15786516. |
to examine the risk of developing type 2 diabetes mellitus among people with schizophrenia exposed to atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone) compared to those exposed to conventional antipsychotics. |
2006-04-19 |
2023-08-12 |
Not clear |
| Rajiv Tando. Suicidal behavior in schizophrenia. Expert review of neurotherapeutics. vol 5. issue 1. 2006-04-18. PMID:15853479. |
the newer generation of atypical antipsychotics (particularly clozapine) and new psychologic approaches (particularly cognitive behavioral therapy) appear to be useful in reducing suicidality in schizophrenia. |
2006-04-18 |
2023-08-12 |
Not clear |
| Vicente Molina, Santiago Reig, Javier Sanz, Tomás Palomo, Carlos Benito, Javier Sánchez, Fernando Sarramea, Javier Pascau, Manuel Desc. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophrenia research. vol 80. issue 1. 2006-04-14. PMID:16150576. |
thus, treatment with risperidone and clozapine in schizophrenia may have an effect on gray and white matter volume and needs further exploration. |
2006-04-14 |
2023-08-12 |
Not clear |
| Adam Wichniak, Tomasz Szafranski, Aleksandra Wierzbicka, Elzbieta Waliniowska, Wojciech Jernajczy. Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment. Journal of psychopharmacology (Oxford, England). vol 20. issue 1. 2006-03-29. PMID:16204327. |
as olanzapine and clozapine share many pharmacological properties, we investigated whether eeg slowing during olanzapine treatment was related to therapy outcome and sleepiness in patients with schizophrenia. |
2006-03-29 |
2023-08-12 |
human |
| Anatoly Kreinin, Dmitri Novitski, Abraham Weizma. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. International clinical psychopharmacology. vol 21. issue 2. 2006-03-28. PMID:16421461. |
the beneficial effect of sulpiride augmentation of clozapine therapy for treatment-resistant schizophrenia patients is enhanced by its antisalivatory effect on clozapine-induced hypersalivation (cih). |
2006-03-28 |
2023-08-12 |
Not clear |